美国权威学术期刊《cell stem cell》2022.8月刊封面图

On the cover: Human iPSCs represent an ideal resource for the production of T cells that could realize “off-the-shelf” adoptive cell therapy. However, the generation of mature, functional iPSC-derived T cells for CAR T cell therapy remains challenging. In this issue, Jing et al. (1181–1196) report that releasing the EZH1-mediated epigenetic suppression of T cell differentiation generates developmentally mature iPSC-T cells with enhanced antitumor activity. The cover image depicts how histone methyltransferase EZH1 functions as a ball and chain for iPSC-T cells. When EZH1 is knocked down (an act represented by the scissors cutting the chain), iPSC-T cells (represented by a warrior) equipped with a chimeric antigen receptor (represented by a car) can more efficiently attack tumor cells. Image credit: Wenjing Wu.

封面：人类 iPSC 是生产 T 细胞的理想资源，可以实现“现成的”过继细胞疗法。 然而，用于 CAR T 细胞治疗的成熟、功能性 iPSC 衍生 T 细胞的产生仍然具有挑战性。 在这个问题上，井 等人。 (1181–1196) 报告说，释放 EZH1 介导的对 T 细胞分化的表观遗传抑制会产生发育成熟的 iPSC-T 细胞，具有增强的抗肿瘤活性。 封面图片描述了组蛋白甲基转移酶 EZH1 如何作为 iPSC-T 细胞的球和链发挥作用。 当 EZH1 被击倒（以剪刀剪断链条为代表的行为）时，配备嵌合抗原受体（以汽车为代表）的 iPSC-T 细胞（以战士为代表）可以更有效地攻击肿瘤细胞。 图片来源：吴文静。